subcutaneous – Talk Bio

AstraZeneca’s Saphnelo Succeeds in Phase III as Self-Injectable Lupus Treatment

12 hours ago talkbio0Tagged anifrolumab, AstraZeneca, Clinical Trials, disease activity, Encephalitis, St. Louis, Lupus Erythematosus, Systemic, Phase III, Saphnelo, Self-Injectable, subcutaneous, TULIP-SC trial

AstraZeneca; Saphnelo; anifrolumab; Phase III; TULIP-SC trial; systemic lupus erythematosus; SLE; self-injectable; subcutaneous; clinical trial; disease activity reduction

Novo Nordisk Plans Phase 3 Trials for Next-Generation Obesity Drug Amycretin

3 months ago talkbio0Tagged amycretin, Clinical Trials, Glucagon-Like Peptide 1, Nordisk, Obesity, Oral cavity, Phase 3, Receptors, Islet Amyloid Polypeptide, subcutaneous, Weight Loss

Novo Nordisk; amycretin; obesity; clinical trials; Phase 3; GLP-1; amylin receptor; weight loss; subcutaneous; oral

Leqembi’s Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost

4 months ago talkbio0Tagged Adoption, Alzheimer 's disease, Approved, AutoInjector, Biogen, dosing, Eisai, Hematologic Tests, launch, Leqembi, Maintenance, Market, subcutaneous, United States Food and Drug Administration

Leqembi; Eisai; Biogen; Alzheimer’s disease; FDA approval; blood test; launch; maintenance dosing; autoinjector; subcutaneous; market adoption

Merck’s Injectable Keytruda Shows Promising Results in Pivotal Trial

6 months ago talkbio0Tagged Clinical Trials, intravenous formula, Keytruda, Non-Small Cell Lung Carcinoma, subcutaneous

Keytruda, subcutaneous injection, intravenous formula, non-small cell lung cancer, pivotal trial, Merck

Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735

6 months ago talkbio0Tagged alpha 1-antitrypsin, Capacity, Contract agreement, CordenPharma, Fill/finish, GLP-1/GIP Dual Agonist, Obesity, oral formulations, production, subcutaneous, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations

FDA Approves Onapgo: Breakthrough Infusion Device for Advanced Parkinson’s Disease

8 months ago talkbio0Tagged apomorphine hydrochloride, Approved, Infusion procedures, motor fluctuations, Onapgo, Parkinson 's disease, subcutaneous, Supernus, United States Food and Drug Administration

Onapgo, apomorphine hydrochloride, Parkinson’s disease, subcutaneous infusion, motor fluctuations, FDA approval, Supernus Pharmaceuticals

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

8 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG